Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients

被引：27
作者：
Ashida, Atsuko [1 ]
Sakaizawa, Kaori [1 ]
Uhara, Hisashi [1 ]
Okuyama, Ryuhei [1 ]
机构：
[1] Shinshu Univ, Sch Med, Dept Dermatol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
来源：
ACTA DERMATO-VENEREOLOGICA | 2017年 / 97卷 / 10期
关键词：
melanoma; circulating tumour DNA; anti-programmed cell death-1 antibody; BRAF; NRAS; droplet digital PCR; METASTATIC MELANOMA; NRAS MUTATIONS; DIGITAL PCR; BRAF; CANCER; RESISTANCE; NIVOLUMAB; THERAPY; UTILITY; PLASMA;
D O I：
10.2340/00015555-2748
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAF(mutant) or NRAS(mutant)) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2-4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.
引用
收藏
页码：1212 / 1218
页数：7
相关论文
共 24 条
  • [1] Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR
    Ashida, Atsuko
    Sakaizawa, Kaori
    Mikoshiba, Asuka
    Uhara, Hisashi
    Okuyama, Ryuhei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (05) : 981 - 988
  • [2] Assessment of BRAF and KIT mutations in Japanese melanoma patients
    Ashida, Atsuko
    Uhara, Hisashi
    Kiniwa, Yukiko
    Oguchi, Misae
    Murata, Hiroshi
    Goto, Yasufumi
    Uchiyama, Aya
    Ogawa, Eisaku
    Hayashi, Koichi
    Koga, Hiroshi
    Okuyama, Ryuhei
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2012, 66 (03) : 240 - 242
  • [3] Final Version of 2009 AJCC Melanoma Staging and Classification
    Balch, Charles M.
    Gershenwald, Jeffrey E.
    Soong, Seng-jaw
    Thompson, John F.
    Atkins, Michael B.
    Byrd, David R.
    Buzaid, Antonio C.
    Cochran, Alistair J.
    Coit, Daniel G.
    Ding, Shouluan
    Eggermont, Alexander M.
    Flaherty, Keith T.
    Gimotty, Phyllis A.
    Kirkwood, John M.
    McMasters, Kelly M.
    Mihm, Martin C., Jr.
    Morton, Donald L.
    Ross, Merrick I.
    Sober, Arthur J.
    Sondak, Vernon K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6199 - 6206
  • [4] Distinct sets of genetic alterations in melanoma
    Curtin, JA
    Fridlyand, J
    Kageshita, T
    Patel, HN
    Busam, KJ
    Kutzner, H
    Cho, KH
    Aiba, S
    Bröcker, EB
    LeBoit, PE
    Pinkel, D
    Bastian, BC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) : 2135 - 2147
  • [5] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
    Diem, S.
    Kasenda, B.
    Spain, L.
    Martin-Liberal, J.
    Marconcini, R.
    Gore, M.
    Larkin, J.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (03) : 256 - 261
  • [6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [7] Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
    Gray, Elin S.
    Rizos, Helen
    Reid, Anna L.
    Boyd, Suzanah C.
    Pereira, Michelle R.
    Lo, Johnny
    Tembe, Varsha
    Freeman, James
    Lee, Jenny H. J.
    Scolyer, Richard A.
    Siew, Kelvin
    Lomma, Chris
    Cooper, Adam
    Khattak, Muhammad A.
    Meniawy, Tarek M.
    Long, Georgina V.
    Carlino, Matteo S.
    Millward, Michael
    Ziman, Melanie
    [J]. ONCOTARGET, 2015, 6 (39) : 42008 - 42018
  • [8] Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
    Huang, Sharon K.
    Hoon, Dave S. B.
    [J]. MOLECULAR ONCOLOGY, 2016, 10 (03) : 450 - 463
  • [9] NRAS mutation status is an independent prognostic factor in metastatic melanoma
    Jakob, John A.
    Bassett, Roland L., Jr.
    Ng, Chaan S.
    Curry, Jonathan L.
    Joseph, Richard W.
    Alvarado, Gladys C.
    Rohlfs, Michelle L.
    Richard, Jessie
    Gershenwald, Jeffrey E.
    Kim, Kevin B.
    Lazar, Alexander J.
    Hwu, Patrick
    Davies, Michael A.
    [J]. CANCER, 2012, 118 (16) : 4014 - 4023
  • [10] Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
    Lipson, Evan J.
    Velculescu, Victor E.
    Pritchard, Theresa S.
    Sausen, Mark
    Pardoll, Drew M.
    Topalian, Suzanne L.
    Diaz, Luis A., Jr.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
123